Expression of GOLPH3 in patients with non‑small cell lung cancer and xenografts models

Tang,Shicong; Yang,Rirong; Zhou,Xin; Pan,Hong; Liu,Jianlun

doi:10.3892/ol.2018.8340

Expression of GOLPH3 in patients with non‑small cell lung cancer and xenografts models

Authors:
- Shicong Tang
- Rirong Yang
- Xin Zhou
- Hong Pan
- Jianlun Liu
View Affiliations

Affiliations: Department of Breast Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Immunology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Thoracic Surgery, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: March 23, 2018 https://doi.org/10.3892/ol.2018.8340
Pages: 7555-7562
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increased expression of Golgi phosphoprotein 3 (GOLPH3) has been reported to be associated with several types of human cancer. Patient‑derived cancer xenograft models have demonstrated great potential in preclinical studies. In the present study, the link between GOLPH3 expression and survival was examined in patients with non‑small cell lung cancer (NSCLC). Patient‑derived lung cancer xenograft models were established with two different methods. Lastly, the association between GOLPH3 expression and establishment of the xenograft models was explored. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry analysis were used to examine GOLPH3 expression in 60 NSCLC tissues and matched adjacent non‑cancerous tissues (ANT). In addition, tumor pieces from the 60 NSCLC tissues were implanted in the subcutaneous layer and in the subrenal kidney capsule of nude mice. RT‑qPCR, histopathology and immunohistochemistry were used to confirm the human origin of the xenograft tumors. RT‑qPCR was also used to research the mutation status of GOLPH3 in the xenograft tumors. The results demonstrated that NSCLC tissues had higher expression of GOLPH3, at the mRNA and protein level, compared with ANT. High expression of GOLPH3 correlated with poor survival in patients with NSCLC. Successful engraftment was established for 27 tissues in the subrenal kidney capsule and for 16 in the subcutaneous layer of nude mice. The subrenal kidney capsule group demonstrated significantly higher engraftment rates than the subcutaneous layer group. In addition, higher GOLPH3 expression in the tumor tissues was significantly correlated with higher engraftment rates in mice. In both groups, few xenografts lost the GOLPH3 mutation. In summary, GOLPH3 may be an important diagnosis and prognosis indicator in patients with NSCLC. The genotype and phenotype of the xenograft tumors derived from patient lung cancer tissues exhibited significant similarities to the originating primary tumors. High GOLPH3 expression may promote the successful establishment of xenograft models for NSCLC.

View Figures

View References

1	Barton MK: Patients of all ages with advanced non-small cell lung cancer are not receiving chemotherapy. CA Cancer J Clin. 65:337–338. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Sahar L, Portier KM, Ward EM and Jemal A: Cancer death rates in US congressional districts. CA Cancer J Clin. 65:339–344. 2015. View Article : Google Scholar : PubMed/NCBI
4	Wu CC, Taylor RS, Lane DR, Ladinsky MS, Weisz JA and Howell KE: GMx33: A novel family of trans-Golgi proteins identified by proteomics. Traffic. 1:963–975. 2000. View Article : Google Scholar : PubMed/NCBI
5	Dippold HC, Ng MM, Farber-Katz SE, Lee SK, Kerr ML, Peterman MC, Sim R, Wiharto PA, Galbraith KA, Madhavarapu S, et al: GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell. 139:337–351. 2009. View Article : Google Scholar : PubMed/NCBI
6	Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen Y, Yu H, Xia C, Lu Y, Ding X, et al: Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol. 110:195–203. 2012. View Article : Google Scholar : PubMed/NCBI
7	Abraham RT: GOLPH3 links the Golgi network to mTOR signaling and human cancer. Pigment Cell Melanoma Res. 22:378–379. 2009. View Article : Google Scholar : PubMed/NCBI
8	Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, et al: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature. 459:1085–1090. 2009. View Article : Google Scholar : PubMed/NCBI
9	Buschman MD, Rahajeng J and Field SJ: GOLPH3 links the Golgi, DNA damage, and cancer. Cancer Res. 75:624–627. 2015. View Article : Google Scholar : PubMed/NCBI
10	Tang W, Han M, Ruan B, Jin W, Lou J, Yuan X, Chen D, Chen Y, Shin VY, Jin H and Wang X: Overexpression of GOLPH3 is associated with poor survival in Non-small-cell lung cancer. Am J Transl Res. 8:1756–1762. 2016.PubMed/NCBI
11	Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L and Shen H: Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol. 7:1272012. View Article : Google Scholar : PubMed/NCBI
12	Feng Y, He F, Wu H, Huang H, Zhang L, Han X and Liu J: GOLPH3L is a novel prognostic biomarker for epithelial ovarian cancer. J Cancer. 6:893–900. 2015. View Article : Google Scholar : PubMed/NCBI
13	Zhu K, Zhao Q, Yue J, Shi P, Yan H, Xu X and Wang R: GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer. Oncotarget. 7:68328–68338. 2016. View Article : Google Scholar : PubMed/NCBI
14	Xue Y, Wu G, Liao Y, Xiao G, Ma X, Zou X, Zhang G, Xiao R, Wang X, Liu Q, et al: GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma. Br J Cancer. 110:2250–2260. 2014. View Article : Google Scholar : PubMed/NCBI
15	Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, Chen K, Li J and Song L: Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res. 18:4059–4069. 2012. View Article : Google Scholar : PubMed/NCBI
16	Seol HS, Suh YA, Ryu YJ, Kim HJ, Chun SM, Na DC, Fukamachi H, Jeong SY, Choi EK and Jang SJ: A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically. J Cancer Res Clin Oncol. 139:1471–1480. 2013. View Article : Google Scholar : PubMed/NCBI
17	Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, et al: Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: Potential models for studying tumor progression-related changes. Clin Cancer Res. 12:4043–4054. 2006. View Article : Google Scholar : PubMed/NCBI
18	Morton CL and Houghton PJ: Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2:247–250. 2007. View Article : Google Scholar : PubMed/NCBI
19	van Kempen LC, Ruiter DJ, van Muijen GN and Coussens LM: The tumor microenvironment: A critical determinant of neoplastic evolution. Eur J Cell Biol. 82:539–548. 2003. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR and Hayward SW: Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate. 64:149–159. 2005. View Article : Google Scholar : PubMed/NCBI
21	Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB and Wang YZ: Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: Potential models. Gynecol Oncol. 96:48–55. 2005. View Article : Google Scholar : PubMed/NCBI
22	Zhang XC, Zhang J, Li M, Huang XS, Yang XN, Zhong WZ, Xie L, Zhang L, Zhou M, Gavine P, et al: Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: Useful tools for preclinical studies of targeted therapies. J Transl Med. 11:1682013. View Article : Google Scholar : PubMed/NCBI
23	Rygaard J and Povlsen CO: Heterotransplantation of a human malignant tumour to ‘Nude’ mice. Acta Pathol Microbiol Scand. 77:758–760. 1969. View Article : Google Scholar : PubMed/NCBI
24	Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M and Merk J: Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 14:6456–6468. 2008. View Article : Google Scholar : PubMed/NCBI
25	Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J and Ling YH: Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res. 6:4932–4938. 2000.PubMed/NCBI
26	Nolen RS: AVMA board approves panel on euthanasia report: Updated guidelines cover more species and methods. J Am Vet Med Assoc. 239:12692011.PubMed/NCBI
27	Delgado-Ruiz RA, Guirado Calvo JL and Romanos GE: Bone grafting materials in critical defects in rabbit calvariae. A systematic review and quality evaluation using ARRIVE guidelines. Clin Oral Implants Res. 26:915–930. 2015. View Article : Google Scholar : PubMed/NCBI
28	Marshman E, Ottewell PD, Potten CS and Watson AJ: Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine. J Pathol. 195:285–292. 2001. View Article : Google Scholar : PubMed/NCBI